علاج سرطان الدم النقوي الحاد حديث التشخيص مع طفرة IDH1 في كبار السن (≥55 عامًا) غير المؤهلين للتحريض التقليدي

References

DOI: 10.1182/bloodadvances.2025017934

• For older adults with newly diagnosed AML and an IDH1 mutation considered appropriate for ALT but not for conventional induction and postremission therapy, the ASH guideline panel suggests azacitidine in combination with ivosidenib over azacitidine monotherapy (conditional recommendation based on low certainty in the evidence of effects ⨁⨁◯◯).
• For older adults with newly diagnosed AML and an IDH1 mutation considered appropriate for ALT but not for conventional induction and postremission therapy, the ASH guideline panel suggests using either azacitidine in combination with ivosidenib or an HMA in combination with venetoclax (conditional recommendation based on very low certainty in the evidence of effects ⨁◯◯◯).
• There is moderate-certainty evidence suggesting that azacitidine combined with ivosidenib, when compared with azacitidine alone, probably increases CR or CR with incomplete hematologic recovery (CRi) at the longest follow-up of the included study (RR, 3.34; 95% CI, 1.91-5.85; median, 15 months follow-up).